baber/WOPTO huggingface dataset:
Patent EP-0324782-A4 (EP)
Inventor: IBSEN ROBERT LOUIS
IPC: C03C3/064
Filed: 1987-09-10
Abstract: Ciment pour usage dentaire constitué de porcelaine ionomère tamponnée, comprenant, en combinaison, un mélange d'une poudre fine, dont les particules ont des dimensions de 5 à 10 microns, contenant, en proportions pondérales, 20 à 30 % de silice, 1 à 10 % d'oxyde de bore, 10 à 20 % d'oxyde d'aluminium, 1 à 10 % de fluorure d'aluminium, 30 à 40 % de fluorure de calcium, 1 à 5 % de pentoxyde de phosphore, 1 à 10 % de fluorure d'ammonium, 5 à 20 % en poids de ce qui précède d'oxyde de zinc et 0 à 10 % de dioxyde de titane avec un composant liquide comprenant, en poids, 100 à 80 % d'un acide polyacrylique de bas poids moléculaire en solution aqueuse à 40 %, de 0 à 20 % d'acide d-tartrique. La poudre et le composant liquide sont mélangés dans des proportions pondérales de 1/1 à 5/3.
Patent EP-0291526-A4 (EP)
Title: Programmable multicircuit wall-mounted controller.
Inventor: PEARLMAN GORDON W
IPC: H05B37/02
Filed: 1987-11-24
Abstract: A programmable lighting circuit controller for controlling a plurality of houshold lighting circuits includes a microprocessor (47) and an electronically erasable programmable read only memory (44) for programming the household lighting circuits for a variety of loads. The lighting circuits may be configured as a combination of incandescent and fluorescent loads (22, 24, 26) by designating one output of the controller as a heater circuit for all of the fluorescent loads. The microprocessor is controlled by a set of nonlatching pushbuttons on a front panel which raise and lower lighting levels, set lighting levels in memory and recall preset levels from memory. Phase-controlled triac circuits are employed as the final load control devices.
Patent EP-0397690-A4 (EP)
Title: Electrooptic modulator
IPC: G02F1/03
Filed: 1988-12-20
Abstract: Electrooptic modulator having a single crystal substrate (12) on which are positioned, successively, an inner reflector (18), resonator layer (20) and an outside reflector (24), arranged whereby, by application of electric potential to cause a reverse bias to be applied to the modulator, to permit modulation of light passing through the modulator by varying the electric potential.
Patent EP-0452306-A4 (EP)
IPC: C08L77/00
Filed: 1989-01-04
Abstract: Il apparaît aujourd'hui qu'une combinaison unique d'additifs rend les polyamides semi-cristallins plus aisément façonnables pour la formation par extrusion-soufflage d'éléments rigides creux de configurations diverses. Les compositions se composent essentiellement d'un polyamide semi-cristallin, d'un agent durcisseur particulier, d'un copolymère d'éthylène riche en anhydrides et d'un polytétrafluoroéthylène fibrillaire.
Patent EP-0397775-A4 (EP)
Title: Method for determination of a component of a sample and apparatus therefor
IPC: B01L3/00
Filed: 1988-12-29
Abstract: This invention relates to a method for determining a component of a test sample with a solid support, said support having incorporated therein a removable first monoclonal antibody which binds to said component and a labeled monoclonal antibody or fragment of a monoclonal antibody which binds to said component wherein said first monoclonal antibody and said labeled monoclonal antibody or monoclonal antibody fragment are derived from the same species under conditions favoring formation of a complex of said first monoclonal antibody said component and said labeled monoclonal antibody or fragment, contacting said complex with an immobilized second receptor which binds to said first monoclonal antibody but not to said labeled monoclonal antibody or fragment under conditions favoring formation of a quaternary complex between said first complex and said immobilized receptor, and measuring label either in said quaternary complex or in a residue of said sample as a measure of said component.
Patent EP-0406357-A4 (EP)
Title: Functional recombinantly prepared synthetic protein polymer
IPC: C07K19/00
Filed: 1989-11-07
Abstract: Novel polymers are provided which are produced by recombinant techniques. The polymers are characterized by having a small repeating sequence which provides for strands capable of associating, resulting in useful structural characteristics, where the strands are joined by turns or loops which are flexible and available for interaction with the environment. Specifically, repeating groups of naturally occurring proteins such as silk are modified by introduction of an amino-acid sequence at a site which provides for a turn between strands to provide for readily available oligopeptides capable of interacting with molecules in the environment.
Patent EP-0471037-A4 (EP)
Title: Set of endodontic instruments
IPC: A61C5/02
Filed: 1990-05-02
Abstract: Differences in the diameters of successive cutting instruments, either hand- or engine-powered, within sets of instruments described herein progress sequentially by constant percentages of increase, rather than by constant linear increase as is currently the practice in the dental manufacturing industry.
Patent EP-0425658-A4 (EP)
Title: Method and apparatus for producing an arbitrary excitation spectrum for fourier transform mass spectrometry
IPC: H01J49/38
Filed: 1990-05-17
Abstract: A desired mass domain excitation profile is selected and converted to a frequency domain excitation spectrum in which the frequency of excitation is generally proportional to the inverse of the mass-to-charge ratio. In the direct method of the invention, the specified frequency domain spectrum is converted by inverse Fourier transformation to a time domain waveform and multiplied by an expanded window function. The time domain waveform is forward Fourier transformed to produce a second discrete frequency spectrum each frequency of which is assigned a phase scrambled such that maximum reduction of peak excitation voltage is achieved with no distortion of the excitation amplitude spectrum. The phase-scrambled frequency spectrum is inverse Fourier transformed to produce the final time domain waveform which is used to generate the electric field which excites the ions in an ion cyclotron resonance cell. In the iterative method of the invention, the desired frequency spectrum is phase scrambled such that all frequencies are not in phase in any point in time, an inverse Fourier transform is performed on the phase scrambled frequency spectrum, and the result multipled by a window function. The time domain waveform is forward Fourier transformed to produce an output spectrum which is compared to a reference spectrum to provide correction factors which are used to predistort the magnitude of the final frequency spectrum, and the steps are repeated until the output frequency spectrum is sufficiently close to the reference spectrum, whereafter the time domain waveform corresponding to that output frequency spectrum is applied as the excitation signal.
Patent EP-0474769-A4 (EP)
Title: A method for the detection of anti-streptokinase antibodies
IPC: G01N33/86
Filed: 1990-05-30
Abstract: PCT No. PCT/US90/03080 Sec. 371 Date Jan. 31, 1992 Sec. 102(e) Date Jan. 31, 1992 PCT Filed May 30, 1990 PCT Pub. No. WO90/15153 PCT Pub. Date Dec. 13, 1990.A method is described for the detection of anti-streptokinase antibodies in a sample which comprises detection of a complex between lactate dehydrogenase, streptokinase, and antistreptokinase antibodies. The method is useful for the detection of antistreptokinase antibodies in the serum of patients prior to clinical streptokinase administration.
Patent EP-0543812-A4 (EP)
Inventor: TOMS DENNIS J
IPC: H04B10/2507
Filed: 1990-10-22
Abstract: Un émetteur optique, approprié pour la transmission de signaux analogiques dans des systèmes à fibres optiques, possèdent un dispositif de distorsion réglable (2) qui effectue la distorsion du signal d'entrée dans un dispositif photoémetteur (3) de manière à linéariser la réponse entrée-à-sortie globale de l'émetteur optique. L'émetteur optique possède en outre un circuit de rétroaction (5-15) couplé optiquement à son entrée à la sortie du dispositif photoémetteur (3) et couplé électriquement à une pluralité de ses sorties à une pluralité correspondante de ses entrées des dispositifs de distorsion réglables (2), en vue de modifier le degré et le genre de distorsion en réponse à la sortie du dispositif photoémetteur pour compenser de manière adaptative les non linéarités de l'ensemble du système.
Patent EP-0539516-A4 (EP)
IPC: A61K39/00
Filed: 1991-07-10
Abstract: A composition and method for treating white blood cell deficiency in human beings or animals that includes, as an active pharmaceutical agent, an effective amount of an edible herb extract wherein the edible herb is from the genus Asphodelus, with the active agent being admixed with a pharmaceutically acceptable carrier.
Patent EP-0591218-A4 (EP)
Title: Non-carcinogenic bright stock extracts and deasphalted oils and process for the production thereof
Inventor: BLACKBURN GARY RAY
IPC: C10C3/08
Filed: 1991-06-25
Abstract: Non-carcinogenic asphalts and asphalt blending stocks are produced from reduced hydrocarbon feedstocks. Such non-carcinogenic products are produced by establishing a functional relationship between mutagenicity index and a physical property correlative of hydrocarbon type for the asphalt or asphalt blending stock and determining a critical physical property level which, when achieved, results in a product having a mutagenicity index of less than about 1.0. Process conditions are established so that a product stream achieving the desired physical property level can be produced. Non-carcinogenic asphalts and asphalt blending stocks are then processed utilizing the conditions so established.
Patent EP-0592600-A4 (EP)
Title: Proteins s polypeptides and uses thereof.
Inventor: GRIFFIN JOHN H
IPC: C12P21/08
Filed: 1992-07-02
Abstract: The invention describes protein S polypeptides and anti-PS antibodies capable of inhibiting the binding of proteins to C4BP. The peptides and antibodies are useful in diagnostic methods and systems for purifying or detecting free protein S. In addition, the polypeptides are useful in therapeutic methods as an anti-coagulant. <IMAGE>
Patent EP-0616751-A4 (EP)
Inventor: STUART KEITH O
IPC: H04R9/04
Filed: 1992-08-04
Abstract: Organe de commande (50) de bobine mobile comprenant un noyau en matériau conducteur de flux magnétique (52, 52') possédant un socle (53) et un aimant (54), ainsi qu'une bobine conductrice de courant électrique (56, 56'). Le noyau (52, 52') comporte une première surface (58, 58', 58'') et un passage continu (60) situé dans ladite première surface (58, 58', 58''). Le passage (60) possède une paire de parois opposées (62, 64). L'aimant (54) se trouve en contact étroit avec la première desdites parois (62, 64) et se trouve éloigné de la deuxième desdites parois (62, 64), de façon à constituer un espace libre entre l'aimant (54) et la deuxième des parois (62, 64). L'aimant (54) possède une première face (94) présentant une première polarité magnétique placée en vis-à-vis de la première des parois (62, 64) et une deuxième face (96) présentant une deuxième polarité magnétique contraire, placée en vis-à-vis de l'espace libre. L'aimant (54) est, de plus, éloigné d'une partie inférieure (76) du passage (60), de façon que le flux magnétique est sensiblement normal à partir de la deuxième face (96) lorsqu'il traverse ledit espace libre vers la deuxième des parois (62, 64).
Patent EP-0627034-A4 (EP)
Title: Mains pressure flusher valve.
Inventor: HILL STEPHEN ARCHIBALD
IPC: F16K21/04
Filed: 1993-02-05
Abstract: A mains pressure valve which comprises a main chamber (12) having an inlet chamber (11) for fluid and a discharge chamber (14) for fluid; a piston (17) located in the main chamber (12) which is movable into and out of sealing engagement with the outlet of the main chamber (12) and which defines above it an upper portion (40) of the main chamber (12); a port (35) in the upper portion (40) which permits fluid to flow therethrough; and actuation control (42) associated with the port to regulate the flow of fluid through the port. Upon actuation fluid in the upper portion (40) drains through port (35) allowing piston (17) to rise and mains pressure fluid passes from inlet chamber (11) through main chamber (12) and out discharge chamber (14). Fluid bleeds via flow valve (21) and (22) into upper portion (40) and as port (35) is closed piston (17) closes the valve after a predetermined period.
Patent EP-0649303-A4 (EP)
Title: Substituted arginines and substituted homoarginines and use thereof.
Inventor: GRIFFITH OWEN W
IPC: A61P43/00
Filed: 1993-05-19
Abstract: Guanidino substituted arginines or homoarginines based on monoalkyl carbon-substituted ornithines or lysines, having the formula   <IMAGE>   wherein R is (CH2)yCH3 or H, R' is CH2 or C(H)(CH2)yCH3, and R'' is CH2 or C(H)(CH2)yCH3, with y ranging from 0 to 5, and x is 0 or 1 and Q is an alkyl group containing from 1 to 6 carbon atoms or NH2 or NO2, and only one of R, R' and R'' providing an alkyl substituent on the ornithine or lysine moiety. Preferred compounds are  alpha -methyl-N omega -methyl-DL-arginine, RS- beta -methyl-N omega -methyl-DL-arginine, RS- gamma -methyl-N omega -methyl-DL-arginine,  alpha -methyl-N omega -amino-DL-arginine, RS- beta -methyl-N omega -amino-DL-arginine, RS- gamma -methyl-N omega -amino-DL-arginine,  alpha -methyl-N omega -nitro-DL-arginine, RS- beta -methyl-N omega -nitro-DL-arginine, and RS- gamma -methyl-N omega -nitro-DL-arginine. A composition includes said compound together with a pharmaceutically acceptable carrier. Methods of use are directed to delivering said compound to inducible nitric oxide synthase to inhibit the ability of the enzyme to catalyze the conversion of arginine to nitric oxide, to administering said compound to inhibit pathological overproduction of nitric oxide from arginine and to administering said compound to a subject having systemic hypotension due to the pathological overproduction of nitric oxide and an  alpha 1 adrenergic agonist to increase blood pressure in the subject to a clinically acceptable level.
Patent EP-0618727-A4 (EP)
Title: Encoder and decoder.
Inventor: KONDO TETSUJIRO
IPC: H04N21/236
Filed: 1993-10-13
Abstract: There are provided and encoder (2) which encodes pixel data by an ADRC method; a divider (3) which divides the data from the encoder (2) into a plurality of bit planes; an encoder (4) which encodes the data for every bit plane by run length coding and Hoffman coding; and a framing circuit (5) which adds error correcting codes to the encoded pixel data. The data encoded by the ADRC method are divided into the bit planes for MSB, 2nd MSB, ... LSB, the bit planes are processed by the run length coding and Hoffman coding. Hence it is possible to compress the data with a high compressiblity, and at the same time, minimize the lowering of the restoration capability of the data when errors are created.
Patent EP-0686006-A4 (EP)
Title: Footwear with flashing lights
Inventor: GOLDSTON MARK R
IPC: A43B3/35
Filed: 1993-10-22
Abstract: Footwear (1) adapted to enhance the visibilty of the wearer contains a light source (12), a power source (14), circuitry (15, 16, 17) to connect the power source (14) to the light source (12) , and a pressure switch (18) disposed in the sole (5) of the footwear (1) between the wearer's foot and the ground and adapted to turn the light source (12) off when the wearer's foot is on the ground, and hence static, thereby conserving the power source (14), and to switch the light source (12) on when the wearer's foot is off the ground, and usually moving, thereby providing enhanced visibility of the footwear (1) and its wearer.
Patent EP-0670309-A4 (EP)
Inventor: KOBAYASHI KOJI CENTRAL PHARMAC
IPC: C07D417/06
Filed: 1993-11-17
Abstract: Composé représenté par la formule (I) ou un sel pharmaceutiquement acceptable de ce dernier. Dans cette formule, R représente hydrogène ou acyle; U représente -O-, -CHR1- ou -NR2-, R1 représentant hydrogène ou hétérocycle et R2 représentant hydrogène ou alkyle inférieur remplacés par alcoxycarbonyle inférierur; V représente -O-, -S-, -CHR3- ou -NR4-, R3 représentant hydrogène ou alcoxycarbonyle, et R4 représentant hydrogène, alkyle ou acyle inférieur; W représente méthyle, hétérocycle ou phényle facultativement substitué; X et Y qui peuvent être identiques ou différents représentent chacun -CH¿2?- ou -S-; m représente un entier compris entre 0 et 6; et n représente un entier compris entre 1 et 4. Ce composé possède une puissante activité d'inhibition spécifique contre la prolyle endopeptidase et supprime la décomposition et la désactivation du THR, de la substance P, de la neurotensine, de la vasopressine et autres. On peut par conséquent l'utiliser pour prévenir et/ou traiter la démence et l'amnésie, y compris la maladie d'Alzheimer.
Patent EP-0651661-A4 (EP)
Title: Improved composite irrigation and suction probe.
Inventor: DORSEY JAMES H III
IPC: A61B17/32
Filed: 1994-04-21
Abstract: A composite suction and irrigation probe is provided for performing the functions of irrigation and suction alone or simultaneously with the use of a single trumpet valve. The probe consist of an inner cannula and an outer cannula. In the first embodiment the inner cannula is attached to one probe mount end of the valve body while the outer cannula is attached to a second and opposite probe mount end. The inner cannula is inserted through a common channel of the valve body and the outer cannula. In the second embodiment, the inner cannula is attached to the outer cannula prior to attaching the probe to the valve body. The designated suction and irrigation ports located within the common channel of the valve body are isolated from each other to provide discrete and dedicated ports.
Patent EP-0705105-A4 (EP)
Inventor: DUNN T JEFFREY
IPC: A61K49/14
Filed: 1994-05-13
Abstract: On incorpore des ligands capables de former des complexes métalliqiues directement dans des peptides en des endroits non biologiquement actifs. Le complexe métallique sert d'agent bifonctionnel et de module d'espacement. Dans un mode de réalisation, on prépare les ligands en remplaçant une séquence d'espacement peptidique non biologiquement active par Cys-Gly-Gly-Glu(η-)co- (NO ID SEQ:1) ou Cys-Gly-Gly-Lys(ε-)NH-CO(CH2)2-CO (NO ID SEQ:2). Dans ces exemples, les liaisons peptidiques non naturelles sont utilisées pour attacher le ligand à l'extrémité terminale du peptide. Des peptides contenant ces ligands sont également décrits. D'autres ligands d'espacement pouvant être incorporés dans les peptides contiennent les séquences peptidiques naturelles suivantes: -Cys-Gly-His-, -Asp-Gly-Cys-, -Glu-Gly-Cys-, -Gly-Asp-Cys-, et -Gly-Glu-Cys-. Les tripeptides non naturels faisant office de ligands d'espacement contiennent: -Cys-Gly(imidazolyl glycyl)-, -isoCys-Gly-(imidazolyl glycyl)-, et -isoCys-Gly-His-. Lorsque lesdites séquences peptidiques sont présentes dans un espaceur peptidique non biologiquement actif, elles sont capables de former des complexes métalliques avec les ions métalliques voulus, les complexes en résultant servant d'agents bifonctionnels et de molécules d'espacement dans le peptide.
Patent EP-0705503-A4 (EP)
IPC: H04B7/185
Filed: 1994-06-16
Abstract: A frame relay protocol-based earth station interface architecture provides full mesh connectivity for a relatively small number of network stations. The fundamental component of the architecture is a frame relay protocol-based switch (110), which employs a network interface "frame relay" standard to define the muliplexing of multiple virtual ports across single physical communications port. Through address and control fields of its connectivity control software, the frame relay protocol-based switch (110) can be dynamically configured to provide multilayer addressing and device selectivity, thereby enabling point-to-point connectivity of multiple terminal devices, such as a plurality of audio circuits (170-1...170-N), to be effected via a single port. Dial codes on the station side of an audio signal muliplexer link (135) are translated into frame relay addresses (data link connection identifiers) that are added to each frame of data for routing though the network. <IMAGE>
Patent EP-0733630-A4 (EP)
Inventor: OHGI TADAAKI
IPC: C07H19/04
Filed: 1994-12-08
Abstract: Dérivé de nucléoside représenté par la formule générale suivante (I) et présentant une efficacité en tant que remède antiviral et remède contre des tumeurs malignes dans laquelle R représente adémine-9-ylméthyle, guanine-9-ylméthyle, hypoxanthine-9-ylméthyle, thymine-1-ylméthyle, uracile-1-ylméthyle ou cytosine-1-ylméthyle; X et Y représentent chacun indépendemment hydrogène ou hydroxy, à l'exception du cas où X est hydrogène et Y est hydroxy.
Patent EP-0728119-A4 (EP)
Title: Electronically controlled, positive-displacement fluid dispenser
Inventor: BEEBE S SCOTT
IPC: B05C17/00
Filed: 1994-12-16
Abstract: A fluid dispenser system, and method of use thereof primarily in industrial applications requiring the dispensing of fluids such as epoxies, silicones, adhesives, etc., allowing for very precise control of the volume of fluid extruded. The system comprises an ergonomic, handheld applicator accommodating a conventional medical syringe, wherein the ergonomic, handheld applicator is attached by a power cord to an electronic control unit. The applicator is provided with a stepping motor that drives a piston or screw a specific distance in response to an electronic signal generated by the control unit. Displacement of the piston or screw creates a positive pressure on a fluid contained in the syringe, thereby causing fluid extrusion from the syringe.
Patent EP-0750193-A4 (EP)
Title: Method for assaying immunosuppressant
Inventor: KOBAYASHI MASAKAZU
IPC: G01N33/94
Filed: 1995-03-08
Abstract: This invention relates to a method and kit for assaying an immunosuppressant having a calcineurin-inhibiting activity by assaying a complex containing immunophilin, calcineurin, calmodulin, calcium ions and a calcineulin-inhibiting immunosuppressant. According to the invention, it is possible to determine more accurately the total concentration of the substances actually having the immunosuppressant effect in the determination of the level of calcineulin-inhibiting immunosuppressants such as FK506 or cyclosporin A in blood.
Patent EP-0704486-A4 (EP)
Inventor: TAKATANI SHIRO
IPC: G02B6/38
Filed: 1995-03-16
Abstract: Composition résineuse destinée au moulage de pièces détachées de précision, et comprenant 20 à 40 % en poids d'au moins un polyphénylène sulfure ou une résine polyester aromatique thermotrope à cristaux liquides, 15 à 25 % en poids de barbes et 40 à 60 % en poids de fines particules sphériques, la teneur totale en barbes et particules sphériques étant comprise entre 60 et 80 % en poids. L'invention porte également sur une seconde composition résineuse destinée au moulage de pièces de précision, laquelle comprend 20 à 40 % en poids d'au moins un polyphénylène sulfure ou une résine polyester aromatique thermotrope à cristaux liquides, 5 à 25 % en poids de barbes, 40 à 75 % en poids de fines particules sphériques et 0,5 à 3 % en poids d'un agent de couplage silane, la teneur totale en barbes et en particules étant comprise entre 60 et 80 % en poids. Dans la mesure où les compositions susmentionnées permettent d'améliorer les résistances mécaniques sans affecter la précision dimensionnelle, la régularité des surfaces et le faible coefficient de dilatation thermique, elles peuvent être avantageusement utilisées pour le moulage de pièces détachées de précision telles que des manchons et des viroles.